EA
ANIP icon

Ellsworth Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Ellsworth Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-9,914
Closed -$801K – 197
2026
Q2 		$801K Buy
9,914
+396
+4% +$31.8K 0.13% 132
2026
Q1 		$732K Buy
9,518
+1,899
+25% +$148K 0.14% 129
2025
Q4 		$650K Buy
+7,619
New +$660K 0.13% 134

Other funds holding ANIP

OLA
Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Ellsworth Advisors's ANIP Position: Q3 2026 in Review

Ellsworth Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2026, closing a stake of 9,914 shares — an estimated $801K sold.

Ellsworth Advisors first reported a position in ANIP in Q4 2025 and held it in 3 quarters. The position peaked at $801K in Q2 2026. 15 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Ellsworth Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Ellsworth Advisors sold 9,914 ANI Pharmaceuticals shares in Q3 2026, an estimated $801K.
  • Ellsworth Advisors first reported a position in ANI Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Ellsworth Advisors's ANI Pharmaceuticals position peaked at $801K in Q2 2026.
  • 15 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Ellsworth Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.